<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34585475</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-3639</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>Targeting autotaxin impacts disease advance in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>e13022</StartPage><MedlinePgn>e13022</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13022</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/bpa.13022</ELocationID><Abstract><AbstractText>A preclinical strategy to broaden the search of potentially effective treatments in amyotrophic lateral sclerosis (ALS) relies on identifying factors controlling motor neuron (MN) excitability. These partners might be part of still unknown pathogenic pathways and/or useful for the design of new interventions to affect disease progression. In this framework, the bioactive membrane-derived phospholipid lysophosphatidic acid (LPA) affects MN excitability through LPA receptor 1 (LPA<sub>1</sub> ). Furthermore, LPA<sub>1</sub> &#xa0;knockdown is neuroprotective in transgenic ALS SOD1-G93A mice. On this basis, we raised the hypothesis that the major LPA-synthesizing ectoenzyme, autotaxin (ATX), regulates MN excitability and is a potential target to modulate disease development in ALS mice. We show here that PF-8380, a specific ATX inhibitor, reduced intrinsic membrane excitability (IME) of hypoglossal MNs in brainstem slices, supporting that baseline ATX activity regulates MN IME. PF-8380-induced alterations were prevented by a small-interfering RNA directed against mRNA for lpa<sub>1</sub> . These outcomes support that impact of ATX-originated lysophospholipids on MN IME engages, at least, the G-protein-coupled receptor LPA<sub>1</sub> . Interestingly, mRNA<sub>atx</sub> levels increased in the spinal cord of pre-symptomatic (1-2&#xa0;months old) SOD1-G93A mice, thus preceding MN loss. The rise in transcripts levels also occurred in cultured spinal cord MNs from SOD1-G93A embryos, suggesting that mRNA<sub>atx</sub> upregulation in MNs is an etiopathogenic event in the ALS cell model. Remarkably, chronic administration in the drinking water of the orally bioavailable ATX inhibitor PF-8380 delayed MN loss, motor deterioration and prolonged life span in ALS mice. Treatment also led to a reduction in LPA<sub>1</sub> -immunoreactive patches in transgenic animals mostly in MNs. These outcomes support that neuroprotective effects of interfering with ATX in SOD1-G93A mice rely, at least in part, on LPA<sub>1</sub> &#xa0;knockdown in MNs. Therefore, we propose ATX as a potential target and/or a biomarker in ALS and highlight ATX inhibitors as reasonable tools with therapeutic usefulness for this lethal pathology.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Brain Pathology published by John Wiley &amp; Sons Ltd on behalf of International Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gento-Caro</LastName><ForeName>&#xc1;ngela</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>GRUpo de NEuroDEgeneraci&#xf3;n y NeurorREparaci&#xf3;n (GRUNEDERE), &#xc1;rea de Fisiolog&#xed;a, Facultad de Medicina, Universidad de C&#xe1;diz-Instituto de Investigaci&#xf3;n e Innovaci&#xf3;n Biom&#xe9;dica de C&#xe1;diz (INiBICA), C&#xe1;diz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilches-Herrando</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>GRUpo de NEuroDEgeneraci&#xf3;n y NeurorREparaci&#xf3;n (GRUNEDERE), &#xc1;rea de Fisiolog&#xed;a, Facultad de Medicina, Universidad de C&#xe1;diz-Instituto de Investigaci&#xf3;n e Innovaci&#xf3;n Biom&#xe9;dica de C&#xe1;diz (INiBICA), C&#xe1;diz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portillo</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>GRUpo de NEuroDEgeneraci&#xf3;n y NeurorREparaci&#xf3;n (GRUNEDERE), &#xc1;rea de Fisiolog&#xed;a, Facultad de Medicina, Universidad de C&#xe1;diz-Instituto de Investigaci&#xf3;n e Innovaci&#xf3;n Biom&#xe9;dica de C&#xe1;diz (INiBICA), C&#xe1;diz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Forero</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5748-9546</Identifier><AffiliationInfo><Affiliation>GRUpo de NEuroDEgeneraci&#xf3;n y NeurorREparaci&#xf3;n (GRUNEDERE), &#xc1;rea de Fisiolog&#xed;a, Facultad de Medicina, Universidad de C&#xe1;diz-Instituto de Investigaci&#xf3;n e Innovaci&#xf3;n Biom&#xe9;dica de C&#xe1;diz (INiBICA), C&#xe1;diz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-L&#xf3;pez</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2897-6227</Identifier><AffiliationInfo><Affiliation>GRUpo de NEuroDEgeneraci&#xf3;n y NeurorREparaci&#xf3;n (GRUNEDERE), &#xc1;rea de Fisiolog&#xed;a, Facultad de Medicina, Universidad de C&#xe1;diz-Instituto de Investigaci&#xf3;n e Innovaci&#xf3;n Biom&#xe9;dica de C&#xe1;diz (INiBICA), C&#xe1;diz, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LPA1/EDG2</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">autotaxin/ENPP2</Keyword><Keyword MajorTopicYN="N">intrinsic membrane excitability</Keyword><Keyword MajorTopicYN="N">motor neuron</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>7</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34585475</ArticleId><ArticleId IdType="pmc">PMC9048519</ArticleId><ArticleId IdType="doi">10.1111/bpa.13022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Do&#x2010;Ha D, Buskila Y, Ooi L. Impairments in motor neurons, interneurons and astrocytes contribute to hyperexcitability in ALS: underlying mechanisms and paths to therapy. Mol Neurobiol. 2018;55(2):1410&#x2013;8. 10.1007/s12035-017-0392-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0392-y</ArticleId><ArticleId IdType="pubmed">28160214</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty MJ. Driven to decay: excitability and synaptic abnormalities in amyotrophic lateral sclerosis. Brain Res Bull. 2018;140:318&#x2013;33. 10.1016/j.brainresbull.2018.05.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2018.05.023</ArticleId><ArticleId IdType="pubmed">29870780</ArticleId></ArticleIdList></Reference><Reference><Citation>King AE, Woodhouse A, Kirkcaldie MT, Vickers JC. Excitotoxicity in ALS: overstimulation, or overreaction? Exp Neurol. 2016;275 (Pt 1):162&#x2013;71. 10.1016/j.expneurol.2015.09.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.09.019</ArticleId><ArticleId IdType="pubmed">26584004</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae JS, Simon NG, Menon P, Vucic S, Kiernan MC. The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol. 2013;9(2):65&#x2013;74. 10.3988/jcn.2013.9.2.65</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2013.9.2.65</ArticleId><ArticleId IdType="pmc">PMC3633193</ArticleId><ArticleId IdType="pubmed">23626643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, Shibuya K, Sato Y, Misawa S, Nasu S, Sekiguchi Y, et al. Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(7):734&#x2013;8. 10.1136/jnnp-2011-301782</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-301782</ArticleId><ArticleId IdType="pubmed">22566594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragagnin AMG, Shadfar S, Vidal M, Jamali MS, Atkin JD. Motor neuron susceptibility in ALS/FTD. Front Neurosci. 2019;13:532. 10.3389/fnins.2019.00532</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00532</ArticleId><ArticleId IdType="pmc">PMC6610326</ArticleId><ArticleId IdType="pubmed">31316328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non&#x2010;cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187(6):761&#x2013;72. 10.1083/jcb.200908164</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200908164</ArticleId><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a&#x2010;Morales V, Rodr&#xed;guez&#x2010;Bey G, G&#xf3;mez&#x2010;P&#xe9;rez L, Dom&#xed;nguez&#x2010;V&#xed;as G, Gonz&#xe1;lez&#x2010;Forero D, Portillo F, et al. Sp1&#x2010;regulated expression of p11 contributes to motor neuron degeneration by membrane insertion of TASK1. Nat Commun. 2019;10:3784</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6706379</ArticleId><ArticleId IdType="pubmed">31439839</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin AC, Burr K, Borooah S, Foster JD, Cleary EM, Geti I, et al. Human iPSC&#x2010;derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat Commun. 2015;6:5999. 10.1038/ncomms6999</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6999</ArticleId><ArticleId IdType="pmc">PMC4338554</ArticleId><ArticleId IdType="pubmed">25580746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Hughes EG, Shetty AS, Arlotta P, Goff LA, Bergles DE, et al. Changes in the excitability of neocortical neurons in a mouse model of amyotrophic lateral sclerosis are not specific to corticospinal neurons and are modulated by advancing disease. J Neurosci. 2017;37(37):9037&#x2013;53. 10.1523/jneurosci.0811-17.2017</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.0811-17.2017</ArticleId><ArticleId IdType="pmc">PMC5597984</ArticleId><ArticleId IdType="pubmed">28821643</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy F, Lamotte d'Incamps B, Imhoff&#x2010;Manuel RD, Zytnicki D. Early intrinsic hyperexcitability does not contribute to motoneuron degeneration in amyotrophic lateral sclerosis. eLife. 2014;3:e04046. 10.7554/eLife.04046</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.04046</ArticleId><ArticleId IdType="pmc">PMC4227046</ArticleId><ArticleId IdType="pubmed">25313866</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Roselli F, Singh K, Leptien K, Julien JP, Gros&#x2010;Louis F, et al. Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron. 2013;80(1):80&#x2013;96. 10.1016/j.neuron.2013.07.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.027</ArticleId><ArticleId IdType="pubmed">24094105</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez&#x2010;Silva ML, Imhoff&#x2010;Manuel RD, Sharma A, Heckman CJ, Shneider NA, Roselli F, et al. Hypoexcitability precedes denervation in the large fast&#x2010;contracting motor units in two unrelated mouse models of ALS. eLife. 2018;7:e30955. 10.7554/eLife.30955.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.30955</ArticleId><ArticleId IdType="pmc">PMC5922970</ArticleId><ArticleId IdType="pubmed">29580378</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HY, Murata J, Clair T, Polymeropoulos MH, Torres R, Manrow RE, et al. Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem Biophys Res Commun. 1996;218(3):714&#x2013;9. 10.1006/bbrc.1996.0127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1996.0127</ArticleId><ArticleId IdType="pubmed">8579579</ArticleId></ArticleIdList></Reference><Reference><Citation>Herr DR, Chew WS, Satish RL, Ong WY. Pleotropic roles of autotaxin in the nervous system present opportunities for the development of novel therapeutics for neurological diseases. Mol Neurobiol. 2020;57:372&#x2013;92. 10.1007/s12035-019-01719-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-01719-1</ArticleId><ArticleId IdType="pubmed">31364025</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanrieder J, Ewing AG. Spatial elucidation of spinal cord lipid&#x2010; and metabolite&#x2010; regulations in amyotrophic lateral sclerosis. Sci Rep. 2014;4:5266. 10.1038/srep05266</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep05266</ArticleId><ArticleId IdType="pmc">PMC4053717</ArticleId><ArticleId IdType="pubmed">24919836</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Veyrat&#x2010;Durebex C, Bocca C, Patin F, Vourc'h P, Kouassi Nzoughet J, et al. Lipidomics reveals cerebrospinal&#x2010;fluid signatures of ALS. Sci Rep. 2017;7(1):17652. 10.1038/s41598-017-17389-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17389-9</ArticleId><ArticleId IdType="pmc">PMC5732162</ArticleId><ArticleId IdType="pubmed">29247199</ArticleId></ArticleIdList></Reference><Reference><Citation>
Lee JC, Park SM, Kim IY, Sung H, Seong JK, Moon MH. High&#x2010;fat diet&#x2010;induced lipidome perturbations in the cortex, hippocampus, hypothalamus, and olfactory bulb of mice. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863(9):980&#x2013;90. https://pubmed.ncbi.nlm.nih.gov/29787912/
</Citation><ArticleIdList><ArticleId IdType="pubmed">29787912</ArticleId></ArticleIdList></Reference><Reference><Citation>Rancoule C, Dusaulcy R, Treguer K, Gres S, Attane C, Saulnier&#x2010;Blache JS. Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis. Biochimie. 2014;96:140&#x2013;3. 10.1016/j.biochi.2013.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2013.04.010</ArticleId><ArticleId IdType="pubmed">23639740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ning P, Yang B, Li S, Mu X, Shen Q, Hu F, et al. Systematic review of the prognostic role of body mass index in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2019;20(5&#x2013;6):356&#x2013;67. 10.1080/21678421.2019.1587631</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587631</ArticleId><ArticleId IdType="pubmed">30931632</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a&#x2010;Morales V, Montero F, Gonz&#xe1;lez&#x2010;Forero D, Rodr&#xed;guez&#x2010;Bey G, G&#xf3;mez&#x2010;P&#xe9;rez L, Medialdea&#x2010;Wandossell MJ, et al. Membrane&#x2010;derived phospholipids control synaptic neurotransmission and plasticity. PLoS Biol. 2015;13(5):e1002153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4440815</ArticleId><ArticleId IdType="pubmed">25996636</ArticleId></ArticleIdList></Reference><Reference><Citation>Gento&#x2010;Caro &#xc1;, Vilches&#x2010;Herrando E, Garc&#xed;a&#x2010;Morales V, Portillo F, Rodr&#xed;guez&#x2010;Bey G, Gonz&#xe1;lez&#x2010;Forero D, et al. Interfering with lysophosphatidic acid receptor edg2/lpa1 signalling slows down disease progression in SOD1&#x2010;G93A transgenic mice. Neuropathol Appl Neurobiol. 2021;nan.12699. 10.1111/nan.12699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12699</ArticleId><ArticleId IdType="pubmed">33508894</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kress GJ, Dowling MJ, Meeks JP, Mennerick S. High threshold, proximal initiation, and slow conduction velocity of action potentials in dentate granule neuron mossy fibers. J Neurophysiol. 2008;100(1):281&#x2013;91. https://pubmed.ncbi.nlm.nih.gov/18480368/
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493481</ArticleId><ArticleId IdType="pubmed">18480368</ArticleId></ArticleIdList></Reference><Reference><Citation>
Portillo F, Moreno&#x2010;L&#xf3;pez B. Nitric oxide controls excitatory/inhibitory balance in the hypoglossal nucleus during early postnatal development. Brain Struct Funct. 2020;225(9):2871&#x2013;84. https://pubmed.ncbi.nlm.nih.gov/33130922/
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674331</ArticleId><ArticleId IdType="pubmed">33130922</ArticleId></ArticleIdList></Reference><Reference><Citation>
Bannai H, L&#xe9;vi S, Schweizer C, Inoue T, Launey T, Racine V, et al. Activity&#x2010;dependent tuning of inhibitory neurotransmission based on GABAAR diffusion dynamics. Neuron. 2009;62(5):670&#x2013;82. https://pubmed.ncbi.nlm.nih.gov/19524526/
</Citation><ArticleIdList><ArticleId IdType="pubmed">19524526</ArticleId></ArticleIdList></Reference><Reference><Citation>Gierse J, Thorarensen A, Beltey K, Bradshaw&#x2010;Pierce E, Cortes&#x2010;Burgos L, Hall T, et al. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther. 2010;334(1):310&#x2013;7. 10.1124/jpet.110.165845</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.110.165845</ArticleId><ArticleId IdType="pubmed">20392816</ArticleId></ArticleIdList></Reference><Reference><Citation>
Pan HL, Liu BL, Lin W, Zhang YQ. Modulation of Nav1.8 by lysophosphatidic acid in the induction of bone cancer pain. Neurosci Bull. 2016;32(5):445&#x2013;54. https://pubmed.ncbi.nlm.nih.gov/27631681/
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5563765</ArticleId><ArticleId IdType="pubmed">27631681</ArticleId></ArticleIdList></Reference><Reference><Citation>Roselli F, Caroni P. From intrinsic firing properties to selective neuronal vulnerability in neurodegenerative diseases. Neuron. 2015;85(5):901&#x2013;10. 10.1016/j.neuron.2014.12.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.063</ArticleId><ArticleId IdType="pubmed">25741719</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron. 2011;71(1):35&#x2013;48. 10.1016/j.neuron.2011.06.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.06.031</ArticleId><ArticleId IdType="pubmed">21745636</ArticleId></ArticleIdList></Reference><Reference><Citation>Thalman C, Horta G, Qiao L, Endle H, Tegeder I, Cheng H, et al. Synaptic phospholipids as a new target for cortical hyperexcitability and E/I balance in psychiatric disorders. Mol Psychiatry. 2018;23(8):1699&#x2013;710. 10.1038/s41380-018-0053-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0053-1</ArticleId><ArticleId IdType="pmc">PMC6153268</ArticleId><ArticleId IdType="pubmed">29743582</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrakis A, Moolenaar WH. Autotaxin: structure&#x2010;function and signaling. J Lipid Res. 2014;55(6):1010&#x2013;8. 10.1194/jlr.R046391</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R046391</ArticleId><ArticleId IdType="pmc">PMC4031933</ArticleId><ArticleId IdType="pubmed">24548887</ArticleId></ArticleIdList></Reference><Reference><Citation>
Talley EM, Solorzano G, Lei Q, Kim D, Bayliss DA. Cns distribution of members of the two&#x2010;pore&#x2010;domain (KCNK) potassium channel family. J Neurosci. 2001;21(19):7491&#x2013;505. http://www.ncbi.nlm.nih.gov/pubmed/11567039?dopt=Citation
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762917</ArticleId><ArticleId IdType="pubmed">11567039</ArticleId></ArticleIdList></Reference><Reference><Citation>van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol. 2006;26(13):5015&#x2013;22. 10.1128/mcb.02419-05</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.02419-05</ArticleId><ArticleId IdType="pmc">PMC1489177</ArticleId><ArticleId IdType="pubmed">16782887</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem. 2006;281(35):25822&#x2013;30. 10.1074/jbc.M605142200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M605142200</ArticleId><ArticleId IdType="pubmed">16829511</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue M, Ma L, Aoki J, Ueda H. Simultaneous stimulation of spinal NK1 and NMDA receptors produces LPC which undergoes ATX&#x2010;mediated conversion to LPA, an initiator of neuropathic pain. J Neurochem. 2008;107(6):1556&#x2013;65. 10.1111/j.1471-4159.2008.05725.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2008.05725.x</ArticleId><ArticleId IdType="pubmed">19014389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewandowski SA, Fredriksson L, Lawrence DA, Eriksson U. Pharmacological targeting of the PDGF&#x2010;CC signaling pathway for blood&#x2010;brain barrier restoration in neurological disorders. Pharmacol Ther. 2016;167:108&#x2013;19. 10.1016/j.pharmthera.2016.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2016.07.016</ArticleId><ArticleId IdType="pmc">PMC5341142</ArticleId><ArticleId IdType="pubmed">27524729</ArticleId></ArticleIdList></Reference><Reference><Citation>Tigyi G, Hong L, Yakubu M, Parfenova H, Shibata M, Leffler CW. Lysophosphatidic acid alters cerebrovascular reactivity in piglets. Am J Physiol. 1995;268(5 Pt 2):H2048&#x2013;55</Citation><ArticleIdList><ArticleId IdType="pubmed">7771554</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tigyi GJ, Yue J, Norman DD, Szabo E, Balogh A, Balazs L, et al. Regulation of tumor cell &#x2013; Microenvironment interaction by the autotaxin&#x2010;lysophosphatidic acid receptor axis. Adv Biol Regul. 2019;71:183&#x2013;93. https://pubmed.ncbi.nlm.nih.gov/30243984/
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6433480</ArticleId><ArticleId IdType="pubmed">30243984</ArticleId></ArticleIdList></Reference><Reference><Citation>
Singh S, Singh TG. role of nuclear factor kappa B (NF&#x2010;&#x3ba;B) signalling in neurodegenerative diseases: an mechanistic approach. Curr Neuropharmacol. 2020;18(10):918&#x2013;35. https://pubmed.ncbi.nlm.nih.gov/32031074/
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7709146</ArticleId><ArticleId IdType="pubmed">32031074</ArticleId></ArticleIdList></Reference><Reference><Citation>
Gomes C, Cunha C, Nascimento F, Ribeiro JA, Vaz AR, Brites D. Cortical neurotoxic astrocytes with early ALS pathology and miR&#x2010;146a deficit replicate gliosis markers of symptomatic SOD1G93A mouse model. Mol Neurobiol. 2019;56(3):2137&#x2013;58. https://pubmed.ncbi.nlm.nih.gov/29995256/
</Citation><ArticleIdList><ArticleId IdType="pubmed">29995256</ArticleId></ArticleIdList></Reference><Reference><Citation>
Dutta K, Thammisetty SS, Boutej H, Bareil C, Julien JP. Mitigation of ALS pathology by neuron&#x2010;specific inhibition of nuclear factor kappa B signaling. J Neurosci. 2020;40(26):5137&#x2013;54. https://pubmed.ncbi.nlm.nih.gov/32457070/
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314413</ArticleId><ArticleId IdType="pubmed">32457070</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N, Kakita A, Takahashi H, Ihara Y, Nobukuni K, Fujimura H, et al. Increased expression and activation of cytosolic phospholipase A2 in the spinal cord of patients with sporadic amyotrophic lateral sclerosis. Acta Neuropathol. 2010;119(3):345&#x2013;54. 10.1007/s00401-009-0636-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0636-7</ArticleId><ArticleId IdType="pubmed">20066429</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M, Kipiani K, Petri S, Choi DK, Chen J, Calingasan NY, et al. Integrative role of cPLA with COX&#x2010;2 and the effect of non&#x2010;steriodal anti&#x2010;inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2005;93(2):403&#x2013;11. 10.1111/j.1471-4159.2005.03024.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03024.x</ArticleId><ArticleId IdType="pubmed">15816863</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaram JR, Chan ES, Poore CP, Pareek TK, Cheong WF, Shui G, et al. Cdk5/p25&#x2010;induced cytosolic PLA2&#x2010;mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration. J Neurosci. 2012;32(3):1020&#x2013;34. 10.1523/jneurosci.5177-11.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.5177-11.2012</ArticleId><ArticleId IdType="pmc">PMC6621136</ArticleId><ArticleId IdType="pubmed">22262900</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomonov Y, Hadad N, Levy R. Reduction of cytosolic phospholipase A2alpha upregulation delays the onset of symptoms in SOD1G93A mouse model of amyotrophic lateral sclerosis. J Neuroinflammation. 2016;13(1):134. 10.1186/s12974-016-0602-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0602-y</ArticleId><ArticleId IdType="pmc">PMC4888471</ArticleId><ArticleId IdType="pubmed">27250836</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tan Z, Lei H, Guo M, Chen Y, Zhai X. An updated patent review of autotaxin inhibitors (2017&#x2013;present). Expert Opin Ther Pat. 2021;31(5):421&#x2013;34. https://pubmed.ncbi.nlm.nih.gov/33342311/
</Citation><ArticleIdList><ArticleId IdType="pubmed">33342311</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>